SequelSEC

Replimune Group, Inc. REPL

Biological Products, (No Diagnostic Substances) · CIK 0001737953 · Fiscal year ends 0331

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2018-12-31
Operating income
-$10.14M
Fiscal year ended 2018-12-31
Free cash flow
-$6.74M
Fiscal year ended 2018-12-31

Replimune Group, Inc. (REPL) reported revenue of $0 and net income of -$7.67M for the fiscal year ended 2018-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from Replimune Group, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Replimune Group, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312018-09-302018-06-30
Revenue$0$0$0
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$10.14M-$7.10M-$5.88M
Net income-$7.67M-$6.46M-$10.04M
Research & development$7.86M$4.96M$3.94M
Weighted-average diluted sharesUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$2.28M$2.14M$1.94M
Selling & marketingUnavailableUnavailableUnavailable

Balance

Replimune Group, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312018-09-302018-06-30
Cash & equivalents$21.05M$23.28M$12.91M
Total assets$152.19M$153.82M$59.29M
Current assets$144.95M$151.87M$55.22M
Total liabilities$8.95M$3.78M$11.63M
Current liabilities$3.81M$3.74M$4.50M
Total equity incl. NCI$143.24M$150.04M-$38.70M
Temporary (mezzanine) equityUnavailableUnavailable$86.36M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$1.50M$2.07M$2.85M

Cash flow

Replimune Group, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312018-09-302018-06-30
Operating cash flow-$6.10M-$6.38M-$6.86M
Capital expenditures$633.00K$3.00K$116.00K
Investing cash flow$3.80M-$85.11M$4.89M
Financing cash flow$153.00K$101.39M-$195.00K
Net change in cash-$2.23M$9.70M-$2.90M
Stock-based compensation$880.00K$718.00K$225.00K
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortization$37.00K$36.00K$33.00K

Derived

Replimune Group, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2018-12-312018-09-302018-06-30
Free cash flow-$6.74M-$6.39M-$6.98M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio38.06x40.56x12.28x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open REPL in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-K · Filed 2026-06-29View SEC filing
10-Q · Filed 2026-02-03View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-K · Filed 2025-05-22View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.